Chi­na has be­come a CEO-lev­el pri­or­i­ty for multi­na­tion­al phar­ma­ceu­ti­cal com­pa­nies: the trend and the im­pli­ca­tions

Af­ter a “hot” pe­ri­od of rapid growth be­tween 2009 and 2012, and a rel­a­tive­ly “cool­er” pe­ri­od of slow­er growth from 2013 to 2015, Chi­na has once again be­come a top-of-mind pri­or­i­ty for the CEOs of most large, multi­na­tion­al phar­ma­ceu­ti­cal com­pa­nies.

At the In­ter­na­tion­al Phar­ma Fo­rum, host­ed in March in Bei­jing by the R&D Based Phar­ma­ceu­ti­cal As­so­ci­a­tion Com­mit­tee (RD­PAC) and the Phar­ma­ceu­ti­cal Re­search and Man­u­fac­tur­ers of Amer­i­ca (PhRMA), no few­er than sev­en CEOs of ma­jor multi­na­tion­al phar­ma­ceu­ti­cal firms par­tic­i­pat­ed, in­clud­ing GSK, Eli Lil­ly, LEO Phar­ma, Mer­ck KGaA, Pfiz­er, Sanofi and UCB. A few days ear­li­er, the CEOs of sev­er­al oth­er large multi­na­tion­als at­tend­ed the Chi­na De­vel­op­ment Fo­rum, an an­nu­al busi­ness fo­rum host­ed by the re­search arm of Chi­na’s State Coun­cil. It’s hard to imag­ine any oth­er coun­try, ex­cept the US, hav­ing such draw­ing pow­er at CEO lev­el.

What’s be­hind this trend? And more im­por­tant­ly, what are the im­pli­ca­tions?

I see four pri­ma­ry sources of val­ue cre­ation, ap­plic­a­ble across in­dus­tries for multi­na­tion­als op­er­at­ing in Chi­na, and nine main im­pli­ca­tions for phar­ma multi­na­tion­als to pon­der and de­bate.

1. Growth from mil­lions to bil­lions: Chi­na is al­ready a key con­trib­u­tor to the rev­enues and growth of multi­na­tion­al phar­ma com­pa­nies

This trend is not unique to the phar­ma­ceu­ti­cal sec­tor and can al­so be ob­served in medtech as well as the con­sumer and au­to sec­tors. For ex­am­ple, by 2030 Chi­na’s con­tri­bu­tion to glob­al growth in per­son­al con­sump­tion is ex­pect­ed to be equal to that of the US and West­ern Eu­rope com­bined. It is al­ready the largest mar­ket for sev­er­al im­por­tant prod­uct cat­e­gories, rang­ing from lux­u­ry goods to cars.

The trend is made clear in the quar­ter­ly earn­ings re­leas­es of most ma­jor phar­ma­ceu­ti­cal multi­na­tion­als. Their per­for­mance in Chi­na is of­ten a bright spot, and one they in­creas­ing­ly show­case. Some com­pa­nies even po­si­tion Chi­na as a “key pil­lar of fu­ture growth.”

For some, Chi­na is al­ready a top two con­trib­u­tor to to­tal top-line rev­enues, sec­ond on­ly to the US, while for oth­ers, it is the main growth dri­ver. At the end of the sec­ond quar­ter this year, sev­er­al com­pa­nies dis­closed year-to-date Chi­na growth fig­ures well above 30%. Giv­en the scale of busi­ness­es op­er­at­ing in Chi­na to­day—sev­er­al of which have rev­enues in the USD bil­lions—these num­bers have a mean­ing­ful im­pact on glob­al per­for­mance. For some com­pa­nies, Chi­na ac­counts for as much as 25% of glob­al growth.

2. In­no­va­tion: Chi­na is an emerg­ing source of prod­uct, port­fo­lio, and busi­ness mod­el in­no­va­tion

In a re­cent in­ter­view with Chi­na Dai­ly, No­var­tis’ head of glob­al drug de­vel­op­ment and chief med­ical of­fi­cer an­nounced that the com­pa­ny is work­ing on “hav­ing every piv­otal drug de­vel­op­ment pro­gram in­clude Chi­na from the be­gin­ning by de­fault.” Many com­pa­nies are em­bark­ing on that jour­ney, made pos­si­ble by the Na­tion­al Med­ical Prod­ucts Ad­min­is­tra­tion (NM­PA) re­form.

Be­yond pipeline man­age­ment and ac­cel­er­a­tion, com­pa­nies are al­so tap­ping in­to Chi­na’s in­no­va­tion ecosys­tem. In the last three years we have seen As­traZeneca open a Com­mer­cial In­no­va­tion Cen­ter in Wuxi, Sanofi open a glob­al re­search in­sti­tute in Suzhou, Mer­ck KGaA open In­no­va­tion Hubs in sev­er­al lo­ca­tions, J&J in­tro­duce its JLAB con­cept in Shang­hai, No­vo Nordisk open its IN­NO­VO cen­ter in Bei­jing, and Roche an­nounce a new ear­ly re­search cen­ter in Shang­hai. While they may vary in scope and op­er­at­ing mod­els, all these cen­ters typ­i­cal­ly aim at fos­ter­ing in­no­va­tion through part­ner­ships with oth­er play­ers in the ecosys­tem.

3. Glob­al sup­ply chain: Chi­na emerg­ing in a more cen­tral role for bio­phar­ma

Sec­tors such as ad­vanced elec­tron­ics are like­ly to give Chi­na a cen­tral role in their glob­al sup­ply chain. For the bio­phar­ma sec­tor, how­ev­er, the trend is on­ly emerg­ing. While we do see sig­nif­i­cant man­u­fac­tur­ing ca­pac­i­ty for small mol­e­cule or­gan­ic com­pounds in main­land Chi­na—for both the Chi­nese mar­ket and for ex­port—multi­na­tion­al com­pa­nies have so far re­sist­ed adding ca­pac­i­ty for large mol­e­cule man­u­fac­tur­ing. This can be ex­plained by sev­er­al fac­tors, but most no­tably a con­cern around IP pro­tec­tion. One would ex­pect that, over time, this will be­come in­creas­ing­ly man­age­able. Al­ready, we ob­serve that some com­pa­nies, such as Boehringer In­gel­heim, op­er­ate plants for large mol­e­cule con­tract man­u­fac­tur­ing in main­land Chi­na, while oth­ers, like Lon­za, have an­nounced plans to do so.

4. Cap­i­tal and tal­ent: Chi­na’s role ex­pand­ing as a source of both

We have seen this trend play out clear­ly in the world of biotech, with Chi­nese VCs be­ing very ac­tive play­ers in glob­al fund­ing. In fact, in 2018, rough­ly 40% of biotech fund­ing in the US came from Chi­nese sources. We al­so see Chi­na phar­ma­cos and in­vestors—in­clud­ing Luye Phar­ma and Fo­s­un—mak­ing larg­er and larg­er strate­gic in­vest­ments out­side of Chi­na, how­ev­er it is still an ear­ly trend. On the tal­ent side, sev­er­al se­nior ex­ec­u­tives of lead­ing phar­ma com­pa­nies are Chi­na-based. For ex­am­ple, the cur­rent EVP of In­ter­na­tion­al for As­traZeneca and the head of the AP­MA re­gion for No­var­tis are both of Chi­nese ori­gin and based in Shang­hai.

So what does it all mean? Here are a few im­pli­ca­tions, and pre­dic­tions…

Up and up: Chi­na’s im­por­tance in many phar­ma com­pa­nies’ glob­al agen­das will con­tin­ue to rise, with an in­creas­ing num­ber of com­pa­nies man­ag­ing Chi­na as a re­gion, rather than as a coun­try with­in Asia-Pa­cif­ic. This is not to say that the cur­rent mod­el won’t con­tin­ue to work well, but as Chi­na grows big­ger as a coun­try, its ap­petite for in­vest­ment and im­pact on re­gion­al per­for­mance be­comes such that the APAC re­gion will in­creas­ing­ly re­sem­ble a Chi­na+ re­gion. As a re­sult, many com­pa­nies may de­cide to have Chi­na re­port more di­rect­ly to the CEO or to a di­rect re­port to the CEO.

Be­ware of the spot­light: The top-line con­tri­bu­tion of Chi­na to rev­enues and growth will be­come a hot top­ic, giv­en the vis­i­bil­i­ty of these met­rics to glob­al in­vestors. We are reach­ing the point at which per­for­mance in Chi­na can “move a stock.” The chal­lenge, how­ev­er, is pre­dict­ing Chi­na’s fu­ture growth with ac­cu­ra­cy—it re­mains at best a “guessti­mate.” Com­pa­nies will need to man­age ex­pec­ta­tions but could still find them­selves sur­prised by their per­for­mance on a quar­ter by quar­ter ba­sis.

Ex­pect peer pres­sure: As more and more com­pa­nies com­mu­ni­cate to in­vestors about their Chi­na per­for­mance and strat­e­gy, more dis­creet com­pa­nies could be asked by fi­nan­cial an­a­lysts to clar­i­fy their strate­gic stance to­wards the mar­ket. This is not to say that all com­pa­nies should nec­es­sar­i­ly make Chi­na a top pri­or­i­ty. But not do­ing so may in­creas­ing­ly re­quire a clear ex­pla­na­tion.

Be wary of ten­sions emerg­ing with pro­po­nents of the sta­tus quo: As Chi­na takes its right­ful po­si­tion at the glob­al board­room ta­ble, in­ter­nal ten­sions with tra­di­tion­al de­vel­oped mar­kets could in­crease. The rise of Chi­na as a glob­al pri­or­i­ty will in­evitably lead to some soul search­ing in mar­kets where growth prospects are more un­cer­tain or even de­clin­ing. Com­mit­ting to Chi­na re­quires more al­lo­ca­tion of re­sources—par­tic­u­lar­ly cap­i­tal and tal­ent—and will in­evitably lead to dif­fi­cult bud­getary dis­cus­sions as com­pa­nies aim to max­i­mize ROI on a glob­al ba­sis.

Mind the gap in sup­ply chain: De­mand in Chi­na is on a scale not seen else­where in the world. In the last few years, we have wit­nessed some sup­ply chain dis­rup­tion due to the sud­den up­take of de­mand post-re­im­burse­ment, for ex­am­ple. Go­ing for­ward, al­lo­ca­tion of sup­ply to Chi­na could be­come a com­plex strate­gic de­ci­sion that con­sid­ers the sig­nif­i­cant up­side in vol­ume, but will al­so, in some cas­es, need to be weighed against the low­er price point of drugs re­quired to se­cure na­tion­al re­im­burse­ment in Chi­na. The ques­tion of ramp­ing up lo­cal man­u­fac­tur­ing to sup­ply the lo­cal mar­ket will be square­ly on the ta­ble.

Count on the tal­ent mar­ket to heat up: The rapid growth of the mar­ket is cre­at­ing an ex­cep­tion­al en­vi­ron­ment for tal­ent­ed ex­ec­u­tives at both multi­na­tion­al phar­ma and lo­cal Chi­nese biotech com­pa­nies to pur­sue a range of at­trac­tive ca­reer op­por­tu­ni­ties. To stay com­pet­i­tive in this new mar­ket for tal­ent, com­pa­nies will need to fun­da­men­tal­ly re­think their val­ue propo­si­tion to the tal­ent they hope to hire—and re­tain in Chi­na. Just adapt­ing a glob­al recipe for tal­ent man­age­ment may not be enough to sus­tain dif­fer­en­ti­a­tion.

Plan for “fast and slow” in­te­gra­tion with glob­al R&D: In­te­gra­tion with glob­al R&D re­mains a work-in-progress. The strate­gic in­tent is rel­a­tive­ly clear. But the abil­i­ty to ex­e­cute the strat­e­gy re­mains a chal­lenge in the con­text of what is still a de­vel­op­ing in­no­va­tion ecosys­tem. Suc­cess will de­pend on sev­er­al key fac­tors, in­clud­ing: 1) How much a com­pa­ny can mo­ti­vate and mo­bi­lize its glob­al prod­uct lead­ers to ful­ly en­gage the Chi­na team; 2) Clear strate­gic align­ment and ef­fec­tive com­mu­ni­ca­tion be­tween the glob­al and Chi­na prod­uct teams to dri­ve ro­bust strat­e­gy, along with high qual­i­ty and rapid ex­e­cu­tion; 3) A strong and ca­pa­ble Chi­na team that can put Chi­na in­to the glob­al con­text and ef­fec­tive­ly in­flu­ence the glob­al or­ga­ni­za­tion. This is not an easy for­mu­la to fol­low.

Con­sid­er Chi­na a “must-have” on a se­nior ex­ec­u­tive re­sume with glob­al as­pi­ra­tions: Chi­na ex­pe­ri­ence can be a big ca­reer boost and it’s a mes­sage that will be in­creas­ing­ly heard by mid­dle man­age­ment. What bet­ter prov­ing ground for fu­ture se­nior ex­ec­u­tives than ex­pe­ri­ence run­ning their Chi­na busi­ness? Chi­na is a large, volatile mar­ket, where the com­plex­i­ty of en­gage­ment with ex­ter­nal stake­hold­ers is among the high­est any­where, and the pace of ex­ter­nal change is of­ten greater than the pace of in­ter­nal change. We al­ready have ex­am­ples of this trend, in­clud­ing the cur­rent CEOs of Lil­ly, GSK, and Bio­gen Idec who all held se­nior re­spon­si­bil­i­ties in Chi­na at some point in their ca­reer.

Ex­pect the un­ex­pect­ed: Chi­na will not fail to sur­prise us. While the news cov­er­age has been large­ly pos­i­tive for multi­na­tion­als in the last few years—Chi­na’s new “4+7” vol­ume-based pur­chas­ing pol­i­cy aside—some bumps on the road should be ex­pect­ed. Re­silience and com­mit­ment will be test­ed. Ul­ti­mate­ly, Chi­na re­mains a “high risk, high re­ward” mar­ket.

Chi­na is the most ex­cit­ing health­care sto­ry in the world to­day. The lat­est chap­ter of ro­bust per­for­mance by multi­na­tion­als is just an ex­am­ple of that.

If you en­joyed this blog, please share com­ments and con­sid­er read­ing my pri­or en­tries, all avail­able un­der my LinkedIn pro­file. Most re­cent ones in­clude views on re­cent in­vest­ment trends in Chi­na health­care, re­flec­tions on the Cam­bri­an ex­plo­sion of Chi­na biotechs, and per­spec­tives on 8 rea­sons why Chi­na is the most ex­cit­ing health­care sto­ry in the world right now.


Al­so pub­lished on LinkedIn. Franck Le Deu (@fle864) is a Se­nior Part­ner with McK­in­sey & Com­pa­ny, lead­ing the Health­care Prac­tice in Greater Chi­na and serv­ing clients across Asia. 

Cell and Gene Con­tract Man­u­fac­tur­ers Must Em­brace Dig­i­ti­za­tion

The Cell and Gene Industry is growing at a staggering 30% CAGR and is estimated to reach $14B by 20251. A number of cell, gene and stem cell therapy sponsors currently have novel drug substances and products and many rely on Contract Development Manufacturing Organizations (CDMO) to produce them with adherence to stringent regulatory cGMP conditions. Cell and gene manufacturing for both autologous (one to one) and allogenic (one to many) treatments face difficult issues such as: a complex supply chain, variability on patient and cellular level, cell expansion count and a tight scheduling of lot disposition process. This complexity affects quality, compliance and accountability in the entire vein-to-vein process for critically ill patients.

A lab technician works during research on coronavirus at Johnson & Johnson subsidiary Janssen Pharmaceutical in Beerse, Belgium, Wednesday, June 17, 2020. (Virginia Mayo/AP Images)

End­points News ranks all 28 play­ers in the Covid-19 vac­cine race. Here's how it stacks up to­day

The 28 players now in or close to the clinical race to get a Covid-19 vaccine over the finish line are angling for a piece of a multibillion-dollar market. And being first — or among the leaders — will play a big role in determining just how big a piece.

Endpoints News writer Nicole DeFeudis has posted a snapshot of all the companies, universities and hospital-based groups now racing through the clinic, ranking them according to their place in the pipeline as well as the latest remarks available on timelines. And we’ll keep this lineup updated right through the end of the year, as the checkered flags start to fall, possibly as early as October.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 87,200+ biopharma pros reading Endpoints daily — and it's free.

Bayer's Marianne De Backer with Endpoints founder John Carroll, Endpoints@JPM20 (Jeff Rumans for Endpoints News)

UP­DAT­ED: Hunt­ing a block­buster, Bay­er forges an $875M-plus M&A deal to ac­quire women’s health biotech

Bayer has dropped $425 million in cash on its latest women’s health bet, bringing a UK biotech and its non-hormonal menopause treatment into the fold.

KaNDy Therapeutics had its roots in GlaxoSmithKline, which spun out several neuroscience drugs into NeRRe Therapeutics back in 2012. Five years later the team created a new biotech to focus solely on NT-814 — which they considered “one of the few true innovations in women’s health in more than two decades.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 87,200+ biopharma pros reading Endpoints daily — and it's free.

Phase III read­outs spell dis­as­ter for Genen­tech’s lead IBD drug

Roche had big plans for etrolizumab. Eyeing a hyper-competitive IBD and Crohn’s market where they have not historically been a player, the company rolled out 8 different Phase III trials, testing the antibody for two different uses across a range of different patient groups.

On Monday, Roche released results for 4 of those studies, and they mark a decided setback for both the Swiss pharma and their biotech sub Genentech, potentially spelling an end to a drug they put over half-a-decade and millions of dollars behind.

Eisai moves to 200 Metro Blvd. by late 2021 (ON3)

Ei­sai is cre­at­ing a new US cor­po­rate, R&D HQ in Roche’s old Nut­ley, NJ cam­pus

Eight years after Roche pulled up stakes from Nutley, NJ in a major R&D reorganization, Japan’s Eisai is moving its US corporate and research hub into their old campus.

Now the ON3 property, Eisai — a longtime Biogen partner focused on neurodegenerative disorders like Alzheimer’s — will bring together a staff of up to 1,200 employees. And execs are pitching the move to the New Jersey campus as a cultural game-changer.

Bing Li, Debra Yu and Konstantin Poukalov, LianBio

Per­cep­tive births its first in-house start­up — and it's a Chi­na play

Perceptive Advisors is going to China.

The decision dates back two years, chief investment officer Adam Stone tells Endpoints News, when the firm began to figure out how it can, in hedge fund-speak, strategically increase its exposure to a growing biopharma market poised to be a key geographic area in the next several decades. It was a bit of a blindspot for Perceptive, he admits.

As “globalized scientist-investors, we just couldn’t afford to have that blindspot in place,” he says.

Ugur Sahin, BioNTech CEO

Covid-19 roundup: Pfiz­er-backed BioN­Tech plans to seek FDA OK for a new vac­cine 'as ear­ly as' Oc­to­ber — ahead of the elec­tion

BioNTech execs say they’re on track to get their late-stage data on a Covid-19 vaccine — partnered with Pfizer — into the hands of regulators as early as October.

In their Q2 release Tuesday morning, the biotech reported that investigators could have late-stage data as early as October, and they won’t be wasting any time in hustling that over to the FDA.

“I am incredibly proud of our team, who has worked tirelessly to initiate our BNT162 Phase 2b/3 trial in record time and put us in a position to seek regulatory review as early as October of this year, if our trials are successful,” said Ugur Sahin, BioNTech’s CEO and co-founder.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 87,200+ biopharma pros reading Endpoints daily — and it's free.

DFC CEO Adam Boehler and Kodak CEO Jim Continenza (Kodak)

Covid-19 roundup: Cure­Vac beefs up its uni­corn IPO dreams as bil­lion­aire own­er takes this Covid-19 mR­NA play­er on a forced march to Nas­daq; Ko­dak's $765M deal is put on hold

When CureVac initially jotted down $100 million for its IPO raise a couple of weeks ago, it seemed small. The German mRNA player, after all, had jumped into a Covid-19 race that swelled the sails of Moderna and BioNTech by tens of billions. And after raising $640 million in a slate of deals, $100 million in a hot market like this seemed like a pittance in the bigger scheme of things.

Today, we got a look at a figure that probably comes closer to the game-changing number the top execs probably have in mind. Selling 15.3 million shares at the high end of their $14 to $16 range would net a $243 million bounty. Majority owner Dietmar Hopp is putting in another €100 million, bringing the total to around $350 million. And what are the chances they want to do even better than that?

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 87,200+ biopharma pros reading Endpoints daily — and it's free.

Eric Shaff (Seres)

UP­DAT­ED: Af­ter a 4-year so­journ, strug­gling mi­cro­bio­me pi­o­neer Seres claims a break­out PhI­II come­back. And shares re­spond in fren­zied spike

Almost exactly 4 years ago, Seres Therapeutics $MCRB experienced one of those soul-crunching failures that can raise big questions about a biotech’s future. Out front in their pursuit of a gut punch to C. difficile infection (CDI), the Phase II test was a flat failure, and investors wiped out a billion dollars of equity value that never returned in the years that followed.

Seres, though, pressed ahead, changing out CEOs a year ago — bidding Merck vet Roger Pomerantz farewell from the C suite — and pushing through a Phase III, hoping that amping up the dosage would make the key difference. And this morning, they unveiled a claim that they had aced the Phase III and positioned themselves for a run at a landmark FDA OK.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 87,200+ biopharma pros reading Endpoints daily — and it's free.